Welcome to our dedicated page for Jazz Pharmaceuticals news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals stock.
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to improving patients' lives by identifying, developing, and commercializing meaningful products that address unmet medical needs. Headquartered in Dublin, Ireland, with U.S. offices in Palo Alto, CA, and Philadelphia, PA, Jazz Pharmaceuticals employs over 875 people worldwide, fostering a highly collaborative and entrepreneurial culture.
Core Business: Jazz Pharmaceuticals focuses on three main therapeutic areas: sleep, hematology/oncology, and pain. The company's diverse product portfolio includes nine approved therapies across neuroscience and oncology indications. Notable products include Xyrem and Xywav for narcolepsy, Zepzelca for metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, Vyxeos for acute myeloid leukemia, and Epidiolex for severe forms of epilepsy, acquired through the purchase of GW Pharmaceuticals in May 2021.
Recent Achievements: In 2023, Jazz Pharmaceuticals reported strong financial performance, achieving over $3.8 billion in total revenue. The company also completed enrollment for a Phase 3 trial of Zepzelca in first-line small cell lung cancer and advanced several late-stage pipeline projects. In May 2024, the U.S. FDA accepted the Biologics License Application (BLA) for zanidatamab, a HER2-targeted bispecific antibody, with a Priority Review designation for treating biliary tract cancer.
Current Projects: Jazz Pharmaceuticals remains committed to expanding its product portfolio through R&D and strategic acquisitions. Ongoing projects include the development of zanidatamab for multiple HER2-expressing cancers, the Phase 3 trial for the combination of zanidatamab with standard chemotherapy for advanced gastric cancer, and the optimization of Epidiolex for broader epilepsy indications.
Financial Condition: As of December 31, 2023, Jazz Pharmaceuticals reported cash and cash equivalents of $1.6 billion. The company sustained a strong operational cash flow, generating $1.09 billion in 2023. Despite an outstanding long-term debt of $5.8 billion, Jazz's disciplined capital allocation supports continued investment in growth and innovation.
Partnerships: The company has key collaborations with various organizations, including BeiGene, Ltd. for the development of zanidatamab. Additionally, Jazz Pharmaceuticals has a strategic partnership with Life Science Cares to drive social impact through employee volunteerism in the U.S., reinforcing its commitment to community engagement.
Jazz Pharmaceuticals continues to innovate and advance its mission to transform lives through pioneering therapeutics in oncology and neuroscience, positioning itself as a leader in addressing complex and unmet medical needs.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced that the FDA has granted Priority Review for zanidatamab, a HER2-targeted bispecific antibody, to treat HER2-positive metastatic biliary tract cancer (BTC). The target action date is set for November 29, 2024. If approved, zanidatamab will be the first HER2-targeted treatment for this condition. The submission is based on results from the Phase 2b HERIZON-BTC-01 trial, which showed a 41.3% confirmed objective response rate. Further data from this trial will be presented at the ASCO Annual Meeting 2024. Additionally, the Phase 3 HERIZON-BTC-302 trial is ongoing to evaluate zanidatamab in combination with standard-of-care therapy.
Jazz Pharmaceuticals announced a collaboration with Life Science Cares to enhance social impact via employee volunteerism in the U.S. This partnership aligns with Jazz's commitment to local communities where its employees reside. Life Science Cares leverages life sciences' financial and human capital to address poverty and inequality. The program will operate around Jazz's U.S. offices in Palo Alto, Philadelphia, and San Diego, encouraging employees to engage in meaningful volunteer activities. Jazz's Global Volunteer Day Policy allows employees to dedicate one paid workday annually to volunteer. Life Science Cares, active since 2016, has invested over $16 million and 55,000 volunteer hours to combat socio-economic disparities.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will participate in the BofA Securities 2024 Global Health Care Conference on May 15, 2024, in Las Vegas. The fireside chat will be held at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST. An audio webcast will be available via the Investors section of the Jazz Pharmaceuticals website.
Jazz Pharmaceuticals plc is a global biopharma company focused on developing life-changing medicines for serious diseases. The company has a diverse portfolio of treatments for sleep disorders, epilepsy, and cancer. Jazz Pharmaceuticals is headquartered in Dublin, Ireland, with a commitment to serving patients worldwide.
Jazz Pharmaceuticals reported a 12% year-over-year revenue increase driven by key growth drivers Xywav, Epidiolex, and Rylaze. They submitted zanidatamab BLA for 2L BTC, expect to launch in 2025, and affirmed 2024 total revenue guidance at $4.0 to $4.2 billion. Various pipeline catalysts and near-term data releases are anticipated. Financials showed a decrease in Xyrem net product sales, an increase in Epidiolex/Epidyolex net product sales, and Rylaze/Enrylaze net product sales. The company provided extensive updates on their key commercial products, pipeline highlights, financial highlights, and 2024 financial guidance.
Jazz Pharmaceuticals is focusing on taking actions to positively impact the planet during Earth Month. They are reflecting on steps to become more conscious of their actions and promoting sustainable practices. For more information, read their Corporate Sustainability and Social Impact Report.
FAQ
What is the current stock price of Jazz Pharmaceuticals (JAZZ)?
What is the market cap of Jazz Pharmaceuticals (JAZZ)?
What does Jazz Pharmaceuticals specialize in?
What are some key products of Jazz Pharmaceuticals?
Where is Jazz Pharmaceuticals headquartered?
What recent achievements has Jazz Pharmaceuticals made?
What is zanidatamab?
How financially stable is Jazz Pharmaceuticals?
What partnerships does Jazz Pharmaceuticals have?
What is Jazz Pharmaceuticals' approach to business culture?
What are the company's future plans?
How can investors stay informed about Jazz Pharmaceuticals?
